Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mccallum, R. W
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Comparing cardiovascular outcomes in diabetes studies

Roland W Mccallum

Department of Medicine and Diabetes, Royal Alexandra Hospital, Corsebar Road, Paisley, PA2 9PN, UK

Miles Fisher

Wards 4 & 5, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G4 0SF, UK, miles.fisher{at}northglasgow.scot.nhs.uk

iabetes can be considered as a cardiovascular disease leading to the premature death of patients. The increase in cardiovascular risk has been extensively investigated and is associated with a cluster of adverse factors. The effects of various treatments used to affect the pathogenesis of the atherosclerotic process have been investigated in many large trials. A number of issues make the interpretation and comparison of these trials complicated, and in particular the use of a single primary end point such as mortality has been replaced with composite end points. The effects of risk factors and interventions on coronary heart disease (CHD) risk has been converted to cardiovascular disease (CVD) risk for understandable reasons, but this makes the interpretation and comparison of results even more complex. This review provides a critical analysis of outcome studies, highlighting differences in design, end points, patient inclusion and definitions in recent cardiovascular diabetology trials, and examines the potential pitfalls in making unjustified comparisons. Br J Diabetes Vasc Dis 2006; 6:111—18

Key Words: cardiovascular disease • coronary heart disease • diabetes • trials.

References

  • American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998;21:1551-9.[Medline] [Order article via Infotrieve]
  • Donnelly R. Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis 2005;5:325-9.[Abstract/Free Full Text]
  • McCallum RW, Fisher M. From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes. Br J Diabetes Vasc Dis 2005;5:218-25.[Abstract/Free Full Text]
  • Anonymous. JBS 2: Joint British Societies' guidelines on the prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1-v52.[Free Full Text]
  • Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lampe FC, Walker M., Shaper AG, Brindle PM, Whincup PH, Ebrahim S. Endpoints for predicting coronary risk must be clarified. BMJ 2001; 323:396-7.[Free Full Text]
  • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sacks F., Pfeffer M., Moye L. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
  • Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998;98:2513-19.[Abstract/Free Full Text]
  • The Long Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
  • Keech A., Colquohoun D., Best J. et al. Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose. Results from the LIPID trial. Diabetes Care 2003;26:2713-21.[Abstract/Free Full Text]
  • The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
  • Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dormandy JA, Charbonnel B., Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective pioglitazone Clinical Trial in Macrovascular events): a randomized controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The FIELD 5. The FIELD study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The IONA study group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002;359:1269-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scott JF, Robinson GM, French JM et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. Stroke 1999;30:793-9.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Anonymous. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gent M. A randomised blinded trial of clopidogrel versus aspirin in patients at high risk of ischaemic events (CAPRIE) Lancet 1996;348: 1329-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W., Topol EJ Amplified benefits of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-62.[Abstract/Free Full Text]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Parving H-H., Lehnert H., Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
  • Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Anonymous. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
  • Malmberg K., Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005;26: 650-61.[Abstract/Free Full Text]
  • Nathan DM Some answers, more controversy from UKPDS: United Kingdom Prospective Diabetes Study. Lancet 1998;352:832-3.[Web of Science][Medline] [Order article via Infotrieve]
  • Blumfield JD, Sealey JE, Mann SJ et al. Beta-adrenergic blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Svensson P., de Faire U., Sleight P., Yusuf S., Ostergen J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE Substudy. Hypertension 2001;38:e28-e32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marchioli R., Barzi F., Bomba E. et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) Prevenzione. Circulation 2002;105:1897-903.[Abstract/Free Full Text]
  • Skyler JS PROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation. Clin Diab 2006;24:63-5.[Free Full Text]
  • Turner RC, Holman RR, Matthews DR et al. UKPDS VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 111-118 (2006)
DOI: 10.1177/14746514060060030301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mccallum, R. W
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?